Business
Bioasis to Present at the 22nd Annual BIO CEO Investor Conference and the OTC Markets 2020 Virtual Investor Conference
Bioasis to Present at the 22nd Annual BIO CEO Investor Conference and the OTC Markets 2020 Virtual Investor Conference.
About this update from Bioasis Technologies Inc.
[{"type":"text","content":"\nBioasis Technologies Inc. (OTCQB:BIOAF)(TSX.V:BTI), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that Dr. Deborah Rathjen, Executive Chair and Chief Executive Officer of Bioasis will present at the following conferences:\n\n\n22nd Annual Bio CEO Investor Conference (February 10–11, 2020)\n\n\nBioasis company presentation on Monday, February 10, 2020 at 10:00 a.m. ET in the Ziegfeld Room on the Fourth Floor at New York Marriott Marquis, New York, NY.\n\n\nOTC Markets 2020 Virtual Investor Conference (February 20, 2020)\n\n\nBioasis company presentation on Thursday, February 20, 2020 at 11:30 a.m. ET. Please register or login at the Virtual Investor Conferences website to view the presentation.\n\n\nFollow @BioasisUS on Twitter \nFollow Bioasis on LinkedIn\n\n\nBTI-E&P\n\n\nAbout Bioasis\n\n\nBioasis Technologies Inc. is a biopharmaceutical company developing the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The delivery of therapeutics across the blood brain barrier represents the final frontier in treating neurological disorders. The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders. The company maintains headquarters in Guilford, Conn., United States. Bioasis trades on the TSX Venture Exchange under the symbol “BTI” and on the OTCQB under the symbol “BIOAF.” For more information about the company, please visit www.bioasis.us.\n\n\nForward Looking Statements\n\n\nCertain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including the Compan...